New Dual-Action antibody OTP-01 enters human trials for advanced cancers
Disease control
Recruiting now
This study tests an experimental drug called OTP-01 in people with advanced solid tumors that have not responded to other treatments. The drug targets two proteins (PD-1 and VEGFR2) to help the immune system fight cancer and block tumor blood supply. The main goals are to find th…
Phase: PHASE1, PHASE2 • Sponsor: Ottimo Pharma Limited • Aim: Disease control
Last updated May 06, 2026 16:01 UTC